,34 There is growing interest in biomarker panels, such as Gender, Age, AFP-L3, AFP (GALAD), as well as ‘liquid’ biopsies using circulating tumor DNA, which appear to have consistent performance independent of liver disease severity.37 The gene discussed is AFP; the disease is liver disorder.